Logo for LaunchBio Program: Investor ConnectLogo for LaunchBio Program: Investor Connect

Bridging the Gap Between Innovation and Capital

Boston, MA

Investor Connect Live in Boston

A NEW KIND OF EXPOSURE

Program

Calling all early stage Boston area companies!

Building on our successful monthly, invitation-only series, top level investors are connected with promising, early stage, life science entrepreneurs through a curated process and meet in a facilitated conversation. We are proud of the 51% of Investor Connect companies that have received further interest from investors.

This series is for life science founders and C-level executives who are raising funding (Pre-Seed, Seed, Series A, Series B) and interested in expanding their investor network.

If you are interested in participating in our first ever LIVE IN-PERSON Investor Connect event in Boston, please complete the Entrepreneur application by clicking the link here!

 

Agenda

3:30 – 4:00 PM – Arrival & Registration

4:00 – 4:10 PM – Intros – LaunchBio, Prendio, SciShield

4:10 – 4:50 PM – Block 1 (8 x companies)

4:50 – 5:00 PM – Break

5:00 – 5:40 PM – Block 2  (8 x companies)

5:40 – 6:00 PM – General Q&A

6:00 – 7:00 PM – Networking & Reception

Event

Applications will be selected based on meeting the following criteria:

Geography:
Boston and surrounding areas.

Company type:
Companies in a broad range of modalities and therapeutic areas.

Areas of Interest:
Any.

Stage:
Looking for pre-seed or seed stage companies focused on cardiovascular disease or high-potential seed- series A.

Qualifying start-ups can apply here today.

INVESTORS

  • Kathryn Segien

    Kathryn Segien, MBA, Vice President, Hercules Capital

    Katie Segien is a Vice President at Hercules Capital focusing on business development and investments in emerging growth-stage life science and healthcare companies. Katie has been with Hercules for over 12 years and has previously worked at Boston Children’s Hospital in their Innovation & Digital Health Accelerator. She was a Flare Scholar at Flare Capital in Boston in 2018 and remains on their seed fund, Flare Scholar Ventures, providing pre-seed capital to healthcare-focused companies.

  • Janice Bourque

    Janice Bourque, MBA, Managing Director, Hercules Capital

    A managing director in the Life Sciences Group, Janice has more than 25 years of life science experience and focuses on emerging growth stage life science companies. Before joining Hercules in 2010, Janice managed strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners to create a global health fund focused on innovative healthcare investments for emerging and developing countries. Before that, she was Senior Vice President and group head-life sciences for Comerica. Janice also led the Massachusetts Biotechnology Council, the first biotechnology association in the world, for 12 years as President/CEO.

  • Sergine Brutus Sweeney HeadShot

    Sergine Brutus Sweeney, PhD, Venture Associate, Mass General Brigham Ventures

    Sergine Brutus Sweeney is a Venture Associate with Mass General Brigham Ventures focusing on new company creation. She is a translational scientist with a background in cell biology and biomarker development. Sergine previously led translational research programs at PathAI, where she oversaw AI-based histopathology biomarker development strategies for biopharma clients, with a focus on oncology. Sergine holds a BSc from Emory University and a PhD from Harvard University.

  • David Prim

    David Prim, PhD, Senior Associate, Broadview Ventures

    David Prim, PhD, is a Senior Associate at Broadview Ventures. David generally supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement. Prior to joining Broadview, David was a Senior Associate at Locust Walk, a global life sciences transaction firm, where he led engagements for biopharma and medtech clients guiding corporate development strategy and supporting sell-side, buy-side, and financing deal execution.